Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
1.
Breast Cancer Res ; 22(1): 1, 2019 12 31.
Article in English | MEDLINE | ID: mdl-31892325

ABSTRACT

BACKGROUND: Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with trastuzumab plus vinorelbine (arm B) or with trastuzumab plus capecitabine (arm C), in patients with HER2-positive metastatic breast cancer (MBC). METHODS: Eligible patients, with or without brain metastases, had received prior HER2-directed therapy. A dose-escalation phase determined the tolerability of each combination and established a dose for further study. Further, patients were recruited to expansion cohorts in each of the 3 arms to further explore efficacy and safety. RESULTS: The recommended doses of epertinib were 600 mg, 200 mg and 400 mg in arms A, B and C, respectively. The most frequent grade 3/4 adverse event (AE) was diarrhoea in all arms, which was manageable with medical intervention and dose modification. The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9). Notably, 4 of 6 patients previously treated with T-DM1 responded in the arm A expansion cohort (epertinib plus trastuzumab). In the arm C expansion cohort (epertinib plus trastuzumab plus capecitabine), 4 of 7 patients responded despite previous exposure to capecitabine. Measurable regression of brain metastases was observed in patients with CNS target lesions treated in both arms A and C. CONCLUSION: We observed safety, tolerability and encouraging antitumour activity of epertinib combined with trastuzumab, or with trastuzumab plus capecitabine. This supports further evaluation of these combinations in patients with pre-treated HER2-positive MBC, with or without brain metastases. TRIAL REGISTRATION: EudraCT Number: 2013-003894-87; registered 09-September-2013.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Quinazolines/therapeutic use , Receptor, ErbB-2/metabolism , Trastuzumab/therapeutic use , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Brain Neoplasms/drug therapy , Brain Neoplasms/secondary , Breast Neoplasms/pathology , Capecitabine/administration & dosage , Capecitabine/adverse effects , Capecitabine/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Quinazolines/administration & dosage , Quinazolines/adverse effects , Receptor, ErbB-2/antagonists & inhibitors , Trastuzumab/administration & dosage , Trastuzumab/adverse effects , Treatment Outcome , Vinorelbine/administration & dosage , Vinorelbine/adverse effects , Vinorelbine/therapeutic use
2.
Pharmacology ; 99(5-6): 259-267, 2017.
Article in English | MEDLINE | ID: mdl-28214870

ABSTRACT

We investigated the effects of S-777469 (1-[[6-Ethyl-1-[4-fluorobenzyl]-5-methyl-2-oxo-1, 2-dihydropyridine-3-carbonyl]amino]-cyclohexanecarboxylic acid), a novel cannabinoid type 2 receptor (CB2) agonist, on 1-fluoro-2,4-dinitrobenzene (DNFB)-induced ear inflammation and mite antigen-induced dermatitis in mice. The oral administration of S-777469 significantly suppressed DNFB-induced ear swelling in a dose-dependent manner. In addition, S-777469 significantly alleviated mite antigen-induced atopic dermatitis-like skin lesions in NC/Nga mice. A histological analysis revealed that S-777469 significantly reduced the epidermal thickness and the number of mast cells infiltrating skin lesions. We demonstrated that S-777469 inhibited mite antigen-induced eosinophil accumulation in skin lesions and an endogenous CB2 ligand, 2-arachidonoylglycerol (2-AG)-induced eosinophil migration in vitro. Moreover, we confirmed that 2-AG levels significantly increased in skin lesions of mite antigen-induced dermatitis model. Together, these results suggest that S-777469 inhibits skin inflammation in mice by blocking the activities of 2-AG.


Subject(s)
Inflammation/drug therapy , Pyridones/pharmacology , Pyridones/therapeutic use , Receptor, Cannabinoid, CB2/agonists , Skin/drug effects , Skin/pathology , Animals , Arachidonic Acids/antagonists & inhibitors , Arachidonic Acids/metabolism , Cell Migration Assays, Leukocyte , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/metabolism , Dinitrofluorobenzene , Dose-Response Relationship, Drug , Endocannabinoids/antagonists & inhibitors , Endocannabinoids/metabolism , Glycerides/antagonists & inhibitors , Glycerides/metabolism , Inflammation/chemically induced , Male , Mice , Mite Infestations/drug therapy , Mite Infestations/metabolism
3.
Eur J Pharmacol ; 765: 15-23, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26277322

ABSTRACT

Prostaglandin (PG) D2 elicits responses through either the DP1 and/or DP2 receptor. Experimental evidence suggests that stimulation of the DP1 receptor contributes to allergic responses, such that antagonists are considered to be directed therapies for allergic diseases. In this study, we demonstrate the activity of a novel synthetic DP1 receptor antagonist termed asapiprant (S-555739) for the DP1 receptor and other receptors in vitro, and assess the efficacy of asapiprant in several animal models of allergic diseases. We determined the affinity and selectivity of asapiprant for the DP1 receptor in binding assays. In the animal models of allergic rhinitis, changes in nasal resistance, nasal secretion, and cell infiltration in nasal mucosa were assessed after antigen challenge with and without asapiprant. Similarly, in the animal models of asthma, the effect of antigen challenge with and without asapiprant on antigen-induced bronchoconstriction, airway hyper-responsiveness, mucin production, and cell infiltration in lung were assessed. In binding studies, asapiprant exhibited high affinity and selectivity for the DP1 receptor. Significant suppression of antigen-induced nasal resistance, nasal secretion, and cell infiltration in nasal mucosa was observed with asapiprant treatment. In addition, treatment with asapiprant suppressed antigen-induced asthmatic responses, airway hyper-responsiveness, and cell infiltration and mucin production in lung. These results show that asapiprant is a potent and selective DP1 receptor antagonist, and exerts suppressive effects in the animal models of allergic diseases. Thus, asapiprant has potential as a novel therapy for allergic airway diseases.


Subject(s)
Asthma/drug therapy , Disease Models, Animal , Receptors, Prostaglandin/antagonists & inhibitors , Rhinitis, Allergic/drug therapy , Thiophenes/therapeutic use , Animals , Asthma/immunology , Asthma/metabolism , Dogs , Female , Guinea Pigs , Humans , Male , Prostaglandins/chemistry , Prostaglandins/pharmacology , Prostaglandins/therapeutic use , Rats , Rats, Inbred BN , Receptors, Prostaglandin/physiology , Respiratory Hypersensitivity/drug therapy , Respiratory Hypersensitivity/immunology , Respiratory Hypersensitivity/metabolism , Rhinitis, Allergic/immunology , Rhinitis, Allergic/metabolism , Sheep , Thiophenes/chemistry , Thiophenes/pharmacology , Treatment Outcome
4.
Pharmacology ; 95(1-2): 95-103, 2015.
Article in English | MEDLINE | ID: mdl-25721168

ABSTRACT

We have previously reported that S-777469 [1-([6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]amino)-cyclohexanecarboxylic acid], a novel cannabinoid type 2 receptor (CB2) agonist, significantly suppressed compound 48/80-induced scratching behavior in mice in a dose-dependent manner when it was administered orally. Here, we demonstrated that the inhibitory effects of S-777469 on compound 48/80-induced scratching behavior are reversed by pretreatment with SR144528, a CB2-selective antagonist. In addition, we investigated the effects of S-777469 on itch-associated scratching behavior induced by several pruritogenic agents in mice and rats. S-777469 significantly suppressed scratching behavior induced by histamine or substance P in mice or by serotonin in rats. In contrast, the H1-antihistamine fexofenadine clearly inhibited histamine-induced scratching behavior but did not affect scratching behavior induced by substance P or serotonin. Moreover, S-777469 significantly inhibited histamine-induced peripheral nerve firing in mice. In conclusion, these results suggest that S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.


Subject(s)
Neurons/drug effects , Pruritus/drug therapy , Pyridones/pharmacology , Pyridones/therapeutic use , Receptor, Cannabinoid, CB2/agonists , Animals , Behavior, Animal/drug effects , Female , Ganglia, Spinal/cytology , Ganglia, Spinal/metabolism , Histamine , Mice, Inbred ICR , Neurons/metabolism , Neurons/physiology , Pruritus/chemically induced , Pruritus/physiopathology , Rats, Inbred F344 , Receptor, Cannabinoid, CB2/metabolism , Serotonin , Signal Transduction/drug effects , Substance P , p-Methoxy-N-methylphenethylamine
5.
Bioorg Med Chem Lett ; 22(8): 2898-901, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22421019

ABSTRACT

The optimization of a series of 3-carbamoyl 2-pyridone derivatives as CB agonists is reported. These efforts resulted in the discovery of 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid (21), a potent dual CB1/CB2 agonist without CNS side effects induced by CB1 receptor activation. It exhibited strong inhibition of scratching as a 1.0% acetone solution in the pruritic model.


Subject(s)
Antipruritics/chemistry , Drug Discovery , Pyridones/agonists , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB2/agonists , Thiazoles/agonists , Animals , Antipruritics/pharmacology , CHO Cells , Cricetinae , Humans , Mice , Protein Binding/drug effects , Pyridones/chemistry , Pyridones/pharmacology , Thiazoles/chemistry , Thiazoles/pharmacology
6.
Bioorg Med Chem Lett ; 22(8): 2803-6, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22444677

ABSTRACT

The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivatives by adjusting the size of side chain at 1-, 5- and 6-position is reported. The structure-activity relationship around this template lead to the identification of S-777469 as a selective CB2 receptor agonist, which exhibited the significant inhibition of scratching induced by Compound 48/80 at 1.0 mg/kg po and 10 mg/kg po (55% and 61%, respectively).


Subject(s)
Antipruritics/chemistry , Antipruritics/pharmacology , Pyridones/chemical synthesis , Pyridones/pharmacology , Receptor, Cannabinoid, CB2/agonists , Administration, Oral , Animals , Antipruritics/administration & dosage , CHO Cells , Cricetinae , Disease Models, Animal , Inhibitory Concentration 50 , Ligands , Mice , Mice, Inbred ICR , Molecular Structure , Protein Binding/drug effects , Pyridones/chemistry
7.
Bioorg Med Chem Lett ; 22(8): 2894-7, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22437111

ABSTRACT

Our lead compound 1 showed high affinity for both CB1 and CB2 receptors, suggesting the possibility of inducing psychoactive side effects through the CB1 receptor in the brain. To solve this issue, polar functional groups were introduced at the 3-position of the pyridone core of compound 1 to find CB1/2 dual agonists such as 17 and 20 which did not show any CNS side effects.


Subject(s)
Antipruritics , Central Nervous System/drug effects , Pyridones/chemistry , Pyridones/pharmacology , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB2/agonists , Animals , Antipruritics/chemistry , Antipruritics/pharmacology , Behavior, Animal , Carbamates/adverse effects , Carbamates/chemistry , Carbamates/pharmacology , Disease Models, Animal , Humans , Mice , Molecular Structure , Pyridones/adverse effects
8.
Eur J Pharmacol ; 666(1-3): 233-41, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21596028

ABSTRACT

While inhaled glucocorticoids are the best treatment for the majority of chronic asthmatics, there is a small group who do not respond to these drugs or whose disease can only be controlled by high doses of oral glucocorticoids with risks of severe side effects. Therefore, a safe novel anti-asthmatic agent which has a different mechanism from that of glucocorticoids is needed for the management of asthma. We have previously shown that an orally active prostanoid DP receptor antagonist, S-5751, had potent anti-inflammatory effects in guinea pig and sheep asthma models. In this study, using a rat asthma like model, we found that lung neutrophilia and proinflammatory cytokine secretion as well as bronchial hyperresponsiveness and lung eosinophilia were induced by repeated antigen-inhalations after antigen-sensitization. These symptoms are similar to the pathogenesis of symptomatic asthma. Orally-administered prostanoid DP receptor antagonists S-5751 and pinagladin significantly suppressed not only bronchial hyperresponsiveness and lung eosinophilia but also neutrophilia and mucus secretion in the lung, while oral prednisolone inhibited only bronchial hyperresponsiveness and eosinophil infiltration. In addition, prostanoid DP receptor antagonists significantly suppressed interleukin (IL)-1ß, IL-6 and CXCL1 mRNA in contrast to suppression of IL-4 and CCL11 mRNA by prednisolone. The majority of prostanoid DP receptor-expressing cells in both rat and human asthmatic lungs are infiltrative macrophages and/or monocytes. These results suggest that prostanoid DP receptor antagonists utilize different mechanisms from glucocorticoids, and that they would be a novel alternative and/or combination drug for asthma therapy.


Subject(s)
Asthma/drug therapy , Glucocorticoids/pharmacology , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Thiophenes/pharmacology , Acetylcholine/pharmacology , Aged , Animals , Antigens/immunology , Asthma/immunology , Asthma/metabolism , Asthma/physiopathology , Bronchial Hyperreactivity/drug therapy , Bronchial Hyperreactivity/immunology , Bronchial Hyperreactivity/metabolism , Chemokines/genetics , Chemokines/metabolism , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/immunology , Humans , Lung/drug effects , Lung/immunology , Lung/metabolism , Male , Mucus/drug effects , Mucus/metabolism , Neutrophil Infiltration/drug effects , Prednisolone/pharmacology , Protein Transport/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptors, Immunologic/genetics , Receptors, Immunologic/metabolism , Receptors, Prostaglandin/genetics , Receptors, Prostaglandin/metabolism , Thiophenes/therapeutic use , Young Adult
9.
Jpn J Clin Oncol ; 39(5): 303-9, 2009 May.
Article in English | MEDLINE | ID: mdl-19336449

ABSTRACT

OBJECTIVE: Recombinant human interleukin-2 (rhIL-2) has been clinically used in the treatment of renal cell carcinoma (RCC). Sorafenib, a multi-targeted kinase inhibitor, has been approved for RCC as well as IL-2. The purpose of this study was to evaluate the antitumor efficacy of IL-2 combined with sorafenib in three different murine renal cancer models using Renca cells. METHODS: We established the subcutaneous tumor model by inoculating wild-type Renca cells into the backs of BALB/c mice, the pulmonary metastatic tumor model by an intravenous injection of luciferase-expressing Renca cells into the tail vain and the orthotopic tumor model by injecting luciferase-expressing Renca cells into the renal subcapsule. These tumor-bearing mice were treated intra-peritoneally with rhIL-2 and/or per os with sorafenib. The antitumor efficacy was evaluated by measuring the tumor size of the subcutaneous tumor or photon intensity of the pulmonary metastatic tumor and the orthotopic tumor. RESULTS: When rhIL-2 was combined with sorafenib, the antitumor efficacy was significantly augmented in comparison with either rhIL-2 or sorafenib alone in all the models. Sorafenib did not inhibit rhIL-2-induced natural killer cell expansion and rhIL-2 had no effect on the anti-angiogenic activity of sorafenib. CONCLUSIONS: The results suggest that the combination of rhIL-2 and sorafenib may offer significant potential as a novel therapeutic approach for patients with RCC.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Benzenesulfonates/administration & dosage , Carcinoma, Renal Cell/drug therapy , Interleukin-2/administration & dosage , Kidney Neoplasms/drug therapy , Pyridines/administration & dosage , Animals , Cell Line, Tumor , Disease Models, Animal , Female , Flow Cytometry , Immunohistochemistry , Lung Neoplasms/secondary , Mice , Mice, Inbred BALB C , Niacinamide/analogs & derivatives , Phenylurea Compounds , Recombinant Proteins/administration & dosage , Sorafenib
10.
Arch Dermatol Res ; 301(10): 739-46, 2009 Oct.
Article in English | MEDLINE | ID: mdl-18979107

ABSTRACT

Recently, we have reported that the pathophysiological features of dermatitis induced by the repeated application with Dermatophagoides farinae (Df) extract ointment in NC/Nga mice were similar to those observed in the patients with atopic dermatitis. In the present study, we first examined whether the application of Df in other mouse strains could induce dermatitis. The repeated application of Df body (Dfb) ointment to the barrier-disrupted back of ICR, C57BL/6, and Balb/c mice did not cause any apparent skin lesions, although transient increase in serum immunoglobulin E (IgE) levels during antigen application was observed. On the other hand, in NC/Nga mice, dermatitis scores and serum IgE levels increased remarkably, and then these changes sustained for at least 10 days after stopping of antigen elicitation. Using NC/Nga mice, we investigated the contribution of scratching behavior to the development and maintenance of Dfb-induced dermatitis. In correlation with the increase in scratching behavior, erythema, hemorrhage, edema, scarring, erosion and excoriation were observed. Cutting off the hind toenails of mice exhibiting chronic skin lesions dramatically alleviated the dermatitis. From these findings, the onset of skin lesions and its chronically sustained course in Dfb-induced dermatitis in NC/Nga mice were closely associated with increased scratching behavior.


Subject(s)
Antigens, Dermatophagoides/immunology , Dermatitis, Atopic/immunology , Dermatophagoides farinae/immunology , Skin/metabolism , Animals , Antigens, Dermatophagoides/administration & dosage , Cell Extracts/administration & dosage , Dermatitis, Atopic/blood , Dermatitis, Atopic/physiopathology , Disease Models, Animal , Disease Progression , Female , Immunization , Immunoglobulin E/blood , Immunoglobulin E/genetics , Immunoglobulin E/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Pruritus , Skin/immunology , Skin/pathology
11.
J Invest Dermatol ; 129(3): 714-22, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18754035

ABSTRACT

We reported that the Gly573Ser substitution in transient receptor potential vanilloid 3 (TRPV3) led to increased ion channel activity in keratinocytes and caused spontaneous hairlessness in DS-Nh mice. DS-Nh mice also develop allergic and pruritic dermatitis. As the hairless and dermatitis phenotypes were both inherited in an autosomal dominant fashion and could not be segregated from each other, we speculated that TRPV3(Gly573Ser) might be responsible for the dermatitis. Here, we constructed TRPV3(Gly573Ser) transgenic mice, with a putative promoter sequence in the 5' region of TRPV3, to investigate the involvement of TRPV3 in the development of specific types of dermatitis. These transgenic mice spontaneously developed dermatitis, whereas wild-type mice did not display this phenotype when maintained under the same conditions. Histological and serological analyses were carried out to better understand the clinical features of TRPV3(Gly573Ser) transgenic mice. A physiological study revealed that TRPV3(Gly573Ser) induced a higher nerve growth factor response to heat. Finally, C57BL-Nh mice were used to investigate the penetrance of the TRPV3(Gly573Ser) gene for dermatitis. Interestingly, C57BL-Nh mice developed spontaneous scratching behavior, separately from the development of dermatitis. We propose that TRPV3(Gly573Ser) is a cause of pruritus and/or dermatitis associated with scratching, and suggest that TRPV3 may represent a therapeutic target in pruritic dermatitis.


Subject(s)
Dermatitis/metabolism , Hypersensitivity/metabolism , Pruritus/metabolism , TRPV Cation Channels/genetics , TRPV Cation Channels/metabolism , Animals , Glycine/chemistry , Immunoglobulin E/metabolism , Ligands , Mice , Mice, Inbred C57BL , Mice, Transgenic , Phenotype , Promoter Regions, Genetic , Serine/chemistry
12.
Eur J Pharmacol ; 601(1-3): 163-70, 2008 Dec 28.
Article in English | MEDLINE | ID: mdl-18834876

ABSTRACT

We discovered a novel dihydroorotate dehydrogenase (DHO-DH) inhibitor, S-2678 ([2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy) pyridin-3-yl] biphenyl-4-yl]-(3-methyl-2-butenyl) amine). Its inhibitory activity against DHO-DH was more potent than that of A77 1726, an active metabolite of the anti-rheumatic drug leflunomide. S-2678 suppressed immunoglobulin production in mouse B cells and human peripheral blood mononuclear cells in vitro, with little or no inhibition of cell proliferation, probably through inhibition of class switch recombination in the immunoglobulin heavy chain loci in B cells. In vivo antibody production induced by systemic immunization with ovalbumin was dramatically suppressed by oral administration of S-2678, without any toxicological signs. However, S-2678 did not affect T-cell activation in vitro, and cytokine production induced by intravenous anti-CD3 antibody in mice. S-2678 did not affect host defense in a mouse model of Candida infection, whereas leflunomide severely impaired it. In conclusion, S-2678 selectively acts on B cells, resulting in antibody production, which suggests that it is useful for the treatment of humoral immunity-related diseases.


Subject(s)
Biphenyl Compounds/pharmacology , Enzyme Inhibitors/pharmacology , Immunoglobulins/drug effects , Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors , Pyridines/pharmacology , Administration, Oral , Aniline Compounds/pharmacology , Animals , Antibody Formation/drug effects , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Biphenyl Compounds/adverse effects , Cell Proliferation/drug effects , Crotonates , Dihydroorotate Dehydrogenase , Enzyme Inhibitors/adverse effects , Female , Humans , Hydroxybutyrates/pharmacology , Immunoglobulin Heavy Chains/drug effects , Immunoglobulin Heavy Chains/metabolism , Immunoglobulins/biosynthesis , Isoxazoles/adverse effects , Isoxazoles/pharmacology , Leflunomide , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Mice , Mice, Inbred BALB C , Nitriles , Pyridines/adverse effects , Toluidines
13.
Haematologica ; 93(10): 1495-504, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18728031

ABSTRACT

BACKGROUND: Thrombocytopenia is a common problem in the management of patients with cancer and other conditions that affect hematopoietic cells. In previous clinical trials, the polyethylene-glycol-conjugated recombinant human megakaryocyte growth and development factor increased platelet counts in patients with idiopathic thrombocytopenic purpura and solid tumors undergoing chemotherapy. However, antibodies to polyethylene-glycol-conjugated recombinant human megakaryocyte growth and development factor develop in healthy volunteers and patients undergoing chemotherapy and cross-react with endogenous thrombopoietin. As a result, clinical development of polyethylene-glycol-conjugated recombinant human megakaryocyte growth and development factor was discontinued in 1998. The aim of this study was to identify an orally bioavailable human Mpl activator that does not develop autoantibodies against endogenous thrombopoietin. DESIGN AND METHODS: We screened our chemical library and created a novel non-peptidyl thrombopoietin receptor, Mpl activator named butyzamide. We evaluated the effect of butyzamide on megakaryopoiesis in vitro using Ba/F3 cells expressing Mpl and human hematopoietic stem cells. For the evaluation of its in vivo effect, we administered butyzamide orally to immunodeficient NOD/Shi-scid,IL-2R gamma(null) (NOG) mice transplanted with human fetal liver-derived CD34(+) cells and investigated the production of human platelets. RESULTS: Butyzamide specifically reacted with human Mpl and activated the same signal transduction pathway as thrombopoietin. However, unlike thrombopoietin, butyzamide did not react with murine Mpl and was shown to require the histidine residue in the transmembrane domain of Mpl for its agonistic activity. Butyzamide induced colony-forming unit-megakaryocytes and polyploid megakaryocytes from human CD34(+) hematopoietic progenitor cells, and its effects were comparable to those of thrombopoietin. When butyzamide was administered orally at the doses of 10 and 50 mg/kg for 20 days to NOG mice transplanted with human fetal liver-derived CD34(+) cells, the human platelet count increased by 6.2- and 22.9-fold, respectively. CONCLUSIONS: Butyzamide is an orally bioavailable human Mpl activator, and appears to have potential for clinical development as a therapeutic agent for patients with thrombocytopenia.


Subject(s)
Cell Differentiation/drug effects , Megakaryocytes/drug effects , Megakaryocytes/metabolism , Receptors, Thrombopoietin/metabolism , Thiazoles/pharmacology , Animals , Antigens, CD34/metabolism , Blood Platelets/cytology , Blood Platelets/drug effects , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , Humans , Megakaryocytes/cytology , Methacrylates , Mice , Molecular Structure , Peptides/pharmacology , Platelet Aggregation/drug effects , Receptors, Thrombopoietin/genetics , Signal Transduction/drug effects , Thiazoles/chemistry , Thrombopoietin/agonists , Thrombopoietin/metabolism
14.
Eur J Pharmacol ; 590(1-3): 400-8, 2008 Aug 20.
Article in English | MEDLINE | ID: mdl-18598692

ABSTRACT

Pirfenidone, a broad-spectrum antifibrotic agent, is known to have efficacy in certain fibrotic disease models, and is under clinical trials in patients with idiopathic pulmonary fibrosis. We investigated the antifibrotic effect of pirfenidone, and its regulatory effect on various pulmonary cytokines, in bleomycin-induced lung fibrosis in mice at the protein level, using prednisolone as a reference agent. Pirfenidone attenuated the bleomycin-induced pulmonary fibrosis at a minimum effective dose of 30 mg/kg/day t.i.d. from the analysis of lung hydroxyproline content. Both pirfenidone (30, 100 mg/kg/day t.i.d) and prednisolone (3, 15 mg/kg/day q.d.) suppressed lung inflammatory edema; however, prednisolone failed to suppress pulmonary fibrosis, which was significantly suppressed only by pirfenidone. Both pirfenidone and prednisolone suppressed the increase in lung interleukin (IL)-1beta, IL-6, IL-12p40 and monocyte chemoattractant protein (MCP)-1 levels induced by bleomycin. On the other hand, pirfenidone prevented the bleomycin-induced decrease in lung interferon (IFN)-gamma levels, while prednisolone had no such effect. Furthermore, pirfenidone suppressed elevation of lung basic-fibroblast growth factor (bFGF) and transforming growth factor (TGF)-beta1 levels, but prednisolone had no such effect. The increases in lung stroma cell derived factor (SDF)-1alpha and IL-18 were also suppressed. These findings suggest that pirfenidone exerts its antifibrotic effect through regulation of lung IFN-gamma, bFGF and TGF-beta1 levels during the development of bleomycin-induced pulmonary fibrosis in mice. The effect on SDF-1alpha and IL-18 levels may also be related to the antifibrotic effects of pirfenidone.


Subject(s)
Bleomycin/toxicity , Cytokines/biosynthesis , Intercellular Signaling Peptides and Proteins/biosynthesis , Lung/metabolism , Prednisolone/pharmacology , Pulmonary Fibrosis/drug therapy , Pyridones/pharmacology , Animals , Chemokines/biosynthesis , Dose-Response Relationship, Drug , Fibroblast Growth Factor 2/biosynthesis , Interferon-gamma/biosynthesis , Interleukin-12 Subunit p40/biosynthesis , Male , Mice , Mice, Inbred ICR , Prednisolone/therapeutic use , Pulmonary Fibrosis/chemically induced , Pyridones/therapeutic use , Transforming Growth Factor beta1/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis
15.
Pharmacology ; 81(4): 301-11, 2008.
Article in English | MEDLINE | ID: mdl-18287786

ABSTRACT

Cytosolic phospholipase A2alpha (cPLA2alpha) preferentially hydrolyzes membrane phospholipids containing arachidonic acid, resulting in the biosynthesis of eicosanoids such as prostaglandins and leukotrienes. To examine the contribution of cPLA2alpha to skin inflammation, we evaluated the effect of (E)-N-[(2S,4R)-4-[N-(biphenyl-2-ylmethyl)-N-2-methylpropylamino]-1-[2-(2,4-difluorobenzoyl)benzoyl]pyrrolidin- 2-yl]methyl-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl) phenyl]acrylamide (RSC-3388), a potent and selective cPLA2alpha inhibitor, on 2,4,6-trinitro-1-chlorobenzene (TNCB)-induced ear inflammation and mite antigen-induced dermatitis in mice. Topical application of RSC-3388 showed a significant inhibitory activity against TNCB-induced ear swelling and eicosanoid production in mice. Comprehensive expression analysis using Gene-Chip technology and subsequent experiments concerning mRNA and protein expression demonstrated that RSC-3388 clearly reduced the levels of interleukin-1beta, macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta in a TNCB-induced mouse model. In addition, RSC-3388 ointment significantly alleviated atopic dermatitis-like skin lesions induced by repeated application of mite antigen. Furthermore, increased expression of cPLA(2)alpha, assessed by anti-phospho-cPLA2alpha antibody, was observed in the skin lesions of mite-antigen-induced dermatitis. These results indicate that cPLA2alpha is involved in the development of skin inflammation in mice, and RSC-3388 is expected to be useful for the treatment of inflammatory skin disorders such as atopic dermatitis.


Subject(s)
Acrylamides/pharmacology , Dermatitis/drug therapy , Enzyme Inhibitors/pharmacology , Group IV Phospholipases A2/antagonists & inhibitors , Thiazolidinediones/pharmacology , Administration, Cutaneous , Animals , Antigens, Dermatophagoides/immunology , Chemokine CCL3/drug effects , Chemokine CCL3/metabolism , Chemokine CCL4/drug effects , Chemokine CCL4/metabolism , Dermatitis/immunology , Dermatitis/physiopathology , Disease Models, Animal , Female , Gene Expression Regulation/drug effects , Interleukin-1beta/drug effects , Interleukin-1beta/metabolism , Mice , Mice, Inbred BALB C , Oligonucleotide Array Sequence Analysis , Picryl Chloride/toxicity , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Skin/drug effects , Skin/pathology
16.
Eur J Pharmacol ; 578(2-3): 286-91, 2008 Jan 14.
Article in English | MEDLINE | ID: mdl-17927976

ABSTRACT

We examined the role of prostanoid DP receptor in nasal blockage in an experimental allergic rhinitis model in guinea pigs. Local inhalation of prostaglandin D(2) (PGD(2)) to the nasal cavity resulted in an increase in intranasal pressure in guinea pigs actively sensitized by repeated antigen exposure but not in non-sensitized guinea pigs. Nasal hyperresponsiveness was observed when the guinea pigs were exposed to histamine and U-46619 (11alpha, 9alpha-epoxymethano-PGH(2); a thromboxane (TX) A(2) mimetic) after repeated antigen exposure. S-5751 ((Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-ylcarbonylamino)-10-norpinan-3-yl]hept-5-enoic acid), a prostanoid DP receptor antagonist, inhibited not only PGD(2)-induced nasal blockage but also nasal hyperresponsiveness to histamine and U-46619 in sensitized guinea pigs. Combined exposure of the nasal cavity of guinea pigs to an aerosol of PGD(2) with histamine or U-46619 at sub-threshold concentrations synergistically caused a marked increase in intranasal pressure. These responses were significantly suppressed by S-5751. These results suggest that PGD(2) plays a critical role in the increase in intranasal pressure via prostanoid DP receptor, probably through synergistically enhancing the nasal response with other chemical mediators released from mast cells and other inflammatory cells activated by allergens.


Subject(s)
Nasal Mucosa/metabolism , Nasal Obstruction/etiology , Prostaglandin D2/metabolism , Receptors, Immunologic/metabolism , Receptors, Prostaglandin/metabolism , Rhinitis, Allergic, Perennial/metabolism , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Administration, Intranasal , Allergens , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Synergism , Guinea Pigs , Histamine/metabolism , Male , Nasal Obstruction/metabolism , Nasal Obstruction/physiopathology , Nasal Obstruction/prevention & control , Nose/drug effects , Nose/physiopathology , Ovalbumin , Pressure , Prostaglandin D2/administration & dosage , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Rhinitis, Allergic, Perennial/chemically induced , Rhinitis, Allergic, Perennial/complications , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Perennial/physiopathology , Thiophenes/pharmacology , Thiophenes/therapeutic use , Time Factors
17.
Biochem Biophys Res Commun ; 363(3): 479-83, 2007 Nov 23.
Article in English | MEDLINE | ID: mdl-17888882

ABSTRACT

We recently reported that Gly573Ser substitution of the transient receptor potential cation channel, subfamily V member 3 (TRPV3) caused hair loss in DS-Nh mice. To further elucidate the effects of this mutation on the development of the spontaneous hairless phenotype, we examined the temperature-response to epidermal sheets from DS-Nh and DS mice. It was indicated that the mutation was gain-of-function. We also performed genetic and histological analyses with both strain skins. DNA microarray data revealed that the levels of keratin-associated protein 16-1, 16-3, and 16-9 genes related to the anagen phase were decreased in the skins of DS-Nh mice compared with those of three days old DS mice. Histological analysis revealed that the anagen phase persisted in DS-Nh mice, and that the telogen phase was seen in DS but not DS-Nh mice at 21 days of age. Regulation of TRPV3 appears to be important for appropriate hair development in rodents.


Subject(s)
Hair/growth & development , Mutation , TRPV Cation Channels/physiology , Animals , Biological Transport , Calcium/metabolism , Calcium/pharmacokinetics , Epidermal Cells , Epidermis/metabolism , Female , Gene Expression Profiling , Hair/metabolism , Hair Follicle/growth & development , Hair Follicle/metabolism , Male , Mice , Mice, Hairless , Oligonucleotide Array Sequence Analysis , Phenotype , Reverse Transcriptase Polymerase Chain Reaction , TRPV Cation Channels/genetics , Time Factors
18.
Allergol Int ; 56(2): 139-48, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17460441

ABSTRACT

BACKGROUND: Atopic dermatitis is a chronically relapsing inflammatory skin disease. Animal models induced by relevant allergens play a very important role in the elucidation of the disease. The patients with atopic dermatitis are highly sensitized with mite allergens such as Dermatophagoides farinae (Df). Therefore, in the present study, we tried to develop a novel model for atopic dermatitis by repeated application with Df extract ointment. METHODS: Df extract ointment was repeatedly applied to the back of NC/Nga mice together with barrier disruption. Atopic dermatitis-like skin lesions were evaluated by dermatitis scores, skin histology and immunological parameters. The effect of corticosteroid and calcineurin inhibitor was also examined. RESULTS: Repeated application of Df extract ointment caused rapid increase in dermatitis scores. Clinical (skin dryness, erythema, edema and erosion) and histological symptoms (dermal and epidermal thickening, hyperkeratosis, parakeratosis and inflammatory cell infiltration) in this model were very similar to those in human atopic dermatitis. Serum total and Df-specific IgE levels were elevated in this model compared with normal mice, and draining lymph node cells isolated from the mice that exhibited dermatitis produced significant amounts of interleukin-5, interleukin-13 and interferon-gamma after re-stimulation with Df. Furthermore, current first-line drugs for the treatment of human atopic dermatitis, corticosteroid and tacrolimus ointments, were effective against the clinical and histological symptoms in this model. CONCLUSIONS: These results suggest that the model we have established is useful for not only elucidating the pathogenesis of atopic dermatitis but also for evaluating therapeutic agents.


Subject(s)
Allergens/immunology , Dermatitis, Atopic/immunology , Dermatophagoides farinae/immunology , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Adrenal Cortex Hormones/pharmacology , Adrenal Cortex Hormones/therapeutic use , Animals , Betamethasone/analogs & derivatives , Betamethasone/pharmacology , Betamethasone/therapeutic use , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/metabolism , Dermatitis, Atopic/pathology , Female , Immunoglobulin E/blood , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Interferon-gamma/metabolism , Interleukin-13/metabolism , Interleukin-5/metabolism , Lymph Nodes/immunology , Lymph Nodes/metabolism , Mice , Reproducibility of Results , Skin/drug effects , Skin/immunology , Skin/pathology , Tacrolimus/pharmacology , Tacrolimus/therapeutic use
19.
Eur J Pharmacol ; 560(1): 81-8, 2007 Mar 29.
Article in English | MEDLINE | ID: mdl-17307163

ABSTRACT

Prostaglandin (PG) D2, a major cyclooxygenase metabolite generated predominantly from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases via the two PGD2 receptors, prostanoid DP receptor and chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2). Monocytes are known to express the prostanoid DP receptor, however, the role of it in inflammatory responses is still unclear. In the present study, to clarify the functional roles of prostanoid DP receptor on monocytes, we examined the effect of PGD2 on the production of monocyte chemoattractant protein (MCP)-1 and interleukin (IL)-8 from a human monocytic cell line, THP-1. Single activation of prostanoid DP receptor hardly produced any cytokines or chemokines. However, activation with PGD2 in the presence of tumor necrosis factor (TNF)-alpha mediated significant production of MCP-1 and IL-8, but not the other cytokines and chemokines, in comparison to single stimulation with TNF-alpha. In addition, the selective prostanoid DP receptor antagonist, pinagladin ((Z)-7-[(1R,2R,3S,5S)-2-(benzothiophen-3-ylcarbonylamide)-10-norpinan-3-yl]hept-5-enoic acid) inhibited the production of MCP-1 and IL-8 upon combined stimulation with PGD2 and TNF-alpha. The synergistic production of MCP-1 and IL-8 by PGD2 was mimicked by dibutyryl cAMP (db-cAMP) and was inhibited by a protein kinase A (PKA) inhibitor. Our findings suggest that activation of the prostanoid DP receptor on THP-1 cells enhances TNF-alpha-induced MCP-1 and IL-8 production via the cAMP/PKA signaling pathway.


Subject(s)
Chemokine CCL2/metabolism , Chemokines/biosynthesis , Cytokines/biosynthesis , Prostaglandin D2/physiology , Receptors, Immunologic/metabolism , Receptors, Prostaglandin/metabolism , Cell Line, Tumor , Cyclic AMP/metabolism , Cyclic AMP-Dependent Protein Kinases/metabolism , Heptanoic Acids/pharmacology , Humans , Interleukin-8/biosynthesis , Monocytes/metabolism , Protein Kinases/metabolism , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Signal Transduction/physiology , Thiophenes/pharmacology , Tumor Necrosis Factor-alpha
20.
Immunology ; 121(1): 51-61, 2007 May.
Article in English | MEDLINE | ID: mdl-17313488

ABSTRACT

Although the pathogenic role of interleukin-13 (IL-13) is a key for atopic dermatitis (AD), the mechanism of IL-13 production in AD remains unclear. To investigate the role of the T-cell receptor Vbeta (TCR Vbeta) haplotype in the development of dermatitis and the production of IL-13 in the naturally occurring dermatitis model by staphylococcal enterotoxin C (SEC)-producing Staphylococcus aureus, we raised DS-Nh mice harbouring the TCR Vbeta(a) haplotype with a central deletion in the TCRBV gene segments, including TCR Vbeta8S2. Observation and histopathological analysis of the two mouse substrains with spontaneous dermatitis indicated that later onset and weaker severity of AD-like dermatitis were identified in mice with TCR Vbeta(a) compared to those with TCR Vbeta(b). Immunohistochemical examination revealed the infiltration of a large number of CD4-bearing T cells in the skin lesions in mice with TCR Vbeta(b) but not in those with TCR Vbeta(a). Interestingly, much lower levels of serum IL-13 were detected in mice with the TCR Vbeta(a) than in those with the TCR Vbeta(b) haplotype. In vitro, synthetic ligands (Pam(2)CSK4) of toll-like receptor 2 (TLR2) synergistically produced IL-13 with SEC in splenocytes of mice with TCR Vbeta(b) but not of those with TCR Vbeta(a), and natural killer T cells were essential for this synergism. Our findings suggested that this TCR Vbeta-haplotype-dependent synergism with TLR2 plays an important role in the development of AD-like dermatitis in DS-Nh mice.


Subject(s)
Dermatitis, Atopic/genetics , Enterotoxins/immunology , Interleukin-13/biosynthesis , Receptors, Antigen, T-Cell, alpha-beta/genetics , Animals , Cell Proliferation , Cells, Cultured , Collagen/metabolism , Dermatitis, Atopic/immunology , Dermatitis, Atopic/metabolism , Dermatitis, Atopic/pathology , Genetic Predisposition to Disease , Haplotypes , Killer Cells, Natural/immunology , Ligands , Lymphocyte Activation/immunology , Mice , Mice, Inbred Strains , Peptidoglycan/immunology , Polymerase Chain Reaction/methods , Receptors, Antigen, T-Cell, alpha-beta/immunology , Spleen/immunology , Staphylococcus aureus , Superantigens/immunology , Toll-Like Receptor 2/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...